| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus | 67 | 2024 | 5841 | 5.730 |
Why?
|
| Endocrinology | 25 | 2023 | 442 | 4.600 |
Why?
|
| Patient-Centered Care | 23 | 2020 | 1424 | 3.480 |
Why?
|
| Diabetes Mellitus, Type 1 | 20 | 2024 | 3416 | 2.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 41 | 2023 | 12145 | 1.980 |
Why?
|
| Blood Glucose | 24 | 2022 | 6390 | 1.750 |
Why?
|
| Primary Health Care | 18 | 2023 | 4673 | 1.670 |
Why?
|
| Hypoglycemia | 7 | 2022 | 883 | 1.460 |
Why?
|
| Diabetes Complications | 8 | 2018 | 1315 | 1.350 |
Why?
|
| Hyperglycemia | 12 | 2024 | 1375 | 1.350 |
Why?
|
| Self Care | 10 | 2018 | 795 | 1.220 |
Why?
|
| Family Practice | 3 | 2016 | 507 | 1.210 |
Why?
|
| Hypoglycemic Agents | 18 | 2022 | 3086 | 1.200 |
Why?
|
| Pennsylvania | 13 | 2016 | 612 | 1.110 |
Why?
|
| Case Management | 4 | 2013 | 272 | 1.110 |
Why?
|
| Insulin | 18 | 2021 | 6588 | 1.080 |
Why?
|
| Blood Glucose Self-Monitoring | 10 | 2022 | 468 | 0.950 |
Why?
|
| Standard of Care | 20 | 2023 | 550 | 0.850 |
Why?
|
| Podiatry | 2 | 2014 | 28 | 0.830 |
Why?
|
| Education, Continuing | 1 | 2023 | 114 | 0.800 |
Why?
|
| Glucagon | 3 | 2021 | 531 | 0.800 |
Why?
|
| Reference Standards | 19 | 2023 | 1005 | 0.770 |
Why?
|
| Fellowships and Scholarships | 2 | 2020 | 1116 | 0.760 |
Why?
|
| Professional Role | 2 | 2014 | 313 | 0.720 |
Why?
|
| Diabetic Ketoacidosis | 5 | 2024 | 253 | 0.710 |
Why?
|
| Biomedical Technology | 2 | 2018 | 210 | 0.680 |
Why?
|
| Practice Management, Medical | 2 | 2018 | 191 | 0.660 |
Why?
|
| Competitive Bidding | 1 | 2019 | 16 | 0.660 |
Why?
|
| Attitude of Health Personnel | 6 | 2016 | 3882 | 0.660 |
Why?
|
| Reagent Strips | 1 | 2019 | 40 | 0.640 |
Why?
|
| Health Educators | 1 | 2018 | 19 | 0.620 |
Why?
|
| Disease Management | 6 | 2019 | 2508 | 0.620 |
Why?
|
| Health Care Costs | 7 | 2024 | 3238 | 0.620 |
Why?
|
| Organizational Innovation | 7 | 2018 | 538 | 0.610 |
Why?
|
| Blood Chemical Analysis | 1 | 2019 | 436 | 0.560 |
Why?
|
| Patient Care Team | 7 | 2021 | 2513 | 0.560 |
Why?
|
| Quality Improvement | 6 | 2023 | 3801 | 0.560 |
Why?
|
| Cooperative Behavior | 3 | 2016 | 1505 | 0.550 |
Why?
|
| Motivation | 7 | 2017 | 2003 | 0.540 |
Why?
|
| Emergency Medical Services | 2 | 2018 | 1921 | 0.540 |
Why?
|
| Internet | 4 | 2015 | 3094 | 0.530 |
Why?
|
| Humans | 147 | 2024 | 761098 | 0.530 |
Why?
|
| Models, Organizational | 7 | 2018 | 544 | 0.520 |
Why?
|
| Patient Education as Topic | 7 | 2017 | 2316 | 0.510 |
Why?
|
| Models, Economic | 2 | 2016 | 714 | 0.500 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 2019 | 743 | 0.490 |
Why?
|
| Health Care Reform | 4 | 2013 | 1247 | 0.490 |
Why?
|
| Practice Guidelines as Topic | 7 | 2020 | 7400 | 0.460 |
Why?
|
| Comprehensive Health Care | 1 | 2015 | 123 | 0.450 |
Why?
|
| Career Choice | 1 | 2020 | 757 | 0.450 |
Why?
|
| Telemedicine | 6 | 2021 | 3051 | 0.440 |
Why?
|
| Quality Assurance, Health Care | 4 | 2014 | 2165 | 0.440 |
Why?
|
| Nurses | 3 | 2014 | 2476 | 0.440 |
Why?
|
| Societies, Medical | 19 | 2023 | 3923 | 0.420 |
Why?
|
| Insulin Infusion Systems | 2 | 2005 | 217 | 0.420 |
Why?
|
| Health Plan Implementation | 2 | 2016 | 335 | 0.410 |
Why?
|
| United States | 29 | 2024 | 72337 | 0.400 |
Why?
|
| Insulin-Secreting Cells | 1 | 2019 | 897 | 0.390 |
Why?
|
| Self-Help Groups | 1 | 2013 | 192 | 0.390 |
Why?
|
| Health Priorities | 1 | 2014 | 375 | 0.380 |
Why?
|
| Physicians | 3 | 2020 | 4583 | 0.380 |
Why?
|
| Burnout, Professional | 1 | 2020 | 703 | 0.380 |
Why?
|
| Drug Costs | 1 | 2019 | 1183 | 0.370 |
Why?
|
| Patient Protection and Affordable Care Act | 3 | 2016 | 1187 | 0.360 |
Why?
|
| Health Services | 2 | 2024 | 750 | 0.360 |
Why?
|
| Physician Assistants | 1 | 2013 | 190 | 0.360 |
Why?
|
| Health Care Surveys | 2 | 2015 | 2424 | 0.350 |
Why?
|
| Quality of Health Care | 8 | 2018 | 4319 | 0.340 |
Why?
|
| Academic Medical Centers | 2 | 2018 | 2757 | 0.330 |
Why?
|
| Monitoring, Ambulatory | 3 | 2019 | 355 | 0.330 |
Why?
|
| Organizational Culture | 1 | 2013 | 509 | 0.320 |
Why?
|
| Chronic Disease | 7 | 2016 | 9317 | 0.310 |
Why?
|
| Models, Psychological | 1 | 2013 | 828 | 0.310 |
Why?
|
| Directive Counseling | 1 | 2010 | 170 | 0.310 |
Why?
|
| Clinical Trials as Topic | 3 | 2022 | 8000 | 0.290 |
Why?
|
| Interviews as Topic | 3 | 2016 | 2696 | 0.280 |
Why?
|
| Cholesterol, LDL | 3 | 2012 | 2380 | 0.280 |
Why?
|
| Interview, Psychological | 1 | 2010 | 809 | 0.280 |
Why?
|
| Perioperative Care | 2 | 2012 | 1037 | 0.270 |
Why?
|
| Software | 3 | 2019 | 4433 | 0.270 |
Why?
|
| Diabetic Foot | 1 | 2011 | 379 | 0.270 |
Why?
|
| Registries | 3 | 2009 | 8236 | 0.270 |
Why?
|
| Medical Informatics | 1 | 2013 | 733 | 0.260 |
Why?
|
| Length of Stay | 4 | 2016 | 6420 | 0.260 |
Why?
|
| Ophthalmology | 2 | 2010 | 550 | 0.260 |
Why?
|
| United States Agency for Healthcare Research and Quality | 2 | 2016 | 85 | 0.260 |
Why?
|
| Autoantibodies | 2 | 2024 | 2117 | 0.250 |
Why?
|
| Monitoring, Intraoperative | 1 | 2012 | 943 | 0.250 |
Why?
|
| Quality Indicators, Health Care | 2 | 2017 | 1790 | 0.250 |
Why?
|
| Research Design | 2 | 2019 | 6178 | 0.250 |
Why?
|
| Inpatients | 3 | 2012 | 2545 | 0.240 |
Why?
|
| Medicine | 1 | 2013 | 942 | 0.240 |
Why?
|
| Internship and Residency | 2 | 2016 | 5879 | 0.240 |
Why?
|
| Patient Satisfaction | 3 | 2013 | 3450 | 0.240 |
Why?
|
| Cardiovascular Diseases | 3 | 2023 | 15513 | 0.240 |
Why?
|
| Mass Screening | 2 | 2009 | 5425 | 0.220 |
Why?
|
| Child Care | 1 | 2023 | 124 | 0.210 |
Why?
|
| Blood Pressure | 9 | 2015 | 8478 | 0.210 |
Why?
|
| Medication Adherence | 2 | 2014 | 2175 | 0.200 |
Why?
|
| Administrative Personnel | 2 | 2014 | 183 | 0.200 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3094 | 0.200 |
Why?
|
| Patient Readmission | 1 | 2016 | 3268 | 0.200 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3216 | 0.200 |
Why?
|
| Referral and Consultation | 4 | 2021 | 3603 | 0.200 |
Why?
|
| Health Promotion | 1 | 2014 | 2205 | 0.200 |
Why?
|
| Hyperoxia | 2 | 2015 | 258 | 0.190 |
Why?
|
| Female | 41 | 2023 | 392458 | 0.190 |
Why?
|
| Cost-Benefit Analysis | 5 | 2019 | 5494 | 0.180 |
Why?
|
| Pandemics | 1 | 2020 | 8663 | 0.170 |
Why?
|
| Adult | 36 | 2024 | 221083 | 0.170 |
Why?
|
| Prediabetic State | 2 | 2018 | 545 | 0.170 |
Why?
|
| Focus Groups | 4 | 2014 | 1409 | 0.170 |
Why?
|
| Consensus | 6 | 2024 | 3133 | 0.170 |
Why?
|
| Male | 38 | 2021 | 360675 | 0.170 |
Why?
|
| Ribavirin | 1 | 2001 | 394 | 0.160 |
Why?
|
| Delivery of Health Care | 5 | 2021 | 5333 | 0.160 |
Why?
|
| Retinal Vessels | 3 | 2015 | 854 | 0.160 |
Why?
|
| Cyclic AMP | 4 | 1987 | 1463 | 0.160 |
Why?
|
| San Francisco | 1 | 2018 | 162 | 0.160 |
Why?
|
| Health Personnel | 3 | 2023 | 3335 | 0.150 |
Why?
|
| Vasodilation | 2 | 2013 | 966 | 0.150 |
Why?
|
| Pharmacists | 1 | 2021 | 259 | 0.150 |
Why?
|
| Eating | 1 | 2005 | 1535 | 0.150 |
Why?
|
| Physician-Patient Relations | 1 | 2011 | 3238 | 0.150 |
Why?
|
| Middle Aged | 31 | 2020 | 220835 | 0.150 |
Why?
|
| Needs Assessment | 2 | 2017 | 1139 | 0.150 |
Why?
|
| Continuity of Patient Care | 2 | 2016 | 1067 | 0.150 |
Why?
|
| Phosphoenolpyruvate Carboxykinase (GTP) | 2 | 1996 | 40 | 0.150 |
Why?
|
| Diabetic Retinopathy | 3 | 2013 | 1274 | 0.140 |
Why?
|
| Biotechnology | 1 | 2019 | 281 | 0.140 |
Why?
|
| Comorbidity | 4 | 2023 | 10514 | 0.140 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2023 | 709 | 0.140 |
Why?
|
| Endpoint Determination | 1 | 2019 | 590 | 0.140 |
Why?
|
| Vasoconstriction | 2 | 2012 | 592 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 3245 | 0.140 |
Why?
|
| Interferon-alpha | 1 | 2001 | 907 | 0.140 |
Why?
|
| Retinal Diseases | 1 | 2023 | 705 | 0.130 |
Why?
|
| Privacy | 1 | 2018 | 233 | 0.130 |
Why?
|
| Risk Factors | 8 | 2021 | 74219 | 0.130 |
Why?
|
| Nurse's Role | 3 | 2013 | 188 | 0.130 |
Why?
|
| Critical Care | 3 | 2020 | 2690 | 0.130 |
Why?
|
| Computers | 1 | 2018 | 591 | 0.130 |
Why?
|
| Hypertension | 1 | 2016 | 8537 | 0.130 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 1996 | 86 | 0.130 |
Why?
|
| Liver Glycogen | 2 | 1986 | 35 | 0.130 |
Why?
|
| Wounds and Injuries | 2 | 2007 | 2492 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2017 | 4013 | 0.120 |
Why?
|
| Health Services Accessibility | 4 | 2019 | 5427 | 0.120 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2018 | 385 | 0.120 |
Why?
|
| Tomography, Optical Coherence | 1 | 2008 | 2923 | 0.120 |
Why?
|
| Treatment Outcome | 11 | 2019 | 64670 | 0.120 |
Why?
|
| Coronary Artery Bypass | 1 | 2004 | 2193 | 0.120 |
Why?
|
| Aged | 21 | 2024 | 169266 | 0.120 |
Why?
|
| Confidentiality | 1 | 2018 | 607 | 0.120 |
Why?
|
| Nutrition Policy | 1 | 2018 | 466 | 0.110 |
Why?
|
| Hyperglycemic Hyperosmolar Nonketotic Coma | 2 | 2024 | 30 | 0.110 |
Why?
|
| Obesity | 3 | 2023 | 12937 | 0.110 |
Why?
|
| Congresses as Topic | 1 | 2018 | 803 | 0.110 |
Why?
|
| Telecommunications | 1 | 2014 | 79 | 0.110 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 1996 | 433 | 0.110 |
Why?
|
| Ambulatory Care Facilities | 1 | 2019 | 934 | 0.110 |
Why?
|
| Health Behavior | 3 | 2023 | 2641 | 0.110 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 1111 | 0.110 |
Why?
|
| Nurse-Patient Relations | 1 | 2013 | 99 | 0.110 |
Why?
|
| Practice Management | 1 | 2013 | 37 | 0.100 |
Why?
|
| Hepatitis C, Chronic | 1 | 2001 | 1027 | 0.100 |
Why?
|
| Diabetic Angiopathies | 3 | 2015 | 805 | 0.100 |
Why?
|
| History, 21st Century | 1 | 2018 | 1566 | 0.100 |
Why?
|
| Adaptation, Psychological | 2 | 2013 | 2632 | 0.100 |
Why?
|
| Medicare | 2 | 2024 | 6775 | 0.100 |
Why?
|
| Curriculum | 2 | 2016 | 3739 | 0.100 |
Why?
|
| Lipoproteins, LDL | 2 | 2013 | 643 | 0.100 |
Why?
|
| Calcium | 4 | 2006 | 5720 | 0.090 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 1386 | 0.090 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2013 | 225 | 0.090 |
Why?
|
| Nurse Practitioners | 1 | 2014 | 269 | 0.090 |
Why?
|
| Risk Assessment | 3 | 2019 | 24013 | 0.090 |
Why?
|
| Perioperative Period | 1 | 2012 | 252 | 0.090 |
Why?
|
| Withholding Treatment | 1 | 2014 | 616 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 1661 | 0.090 |
Why?
|
| Coronary Disease | 3 | 2015 | 5921 | 0.090 |
Why?
|
| Young Adult | 7 | 2021 | 59199 | 0.080 |
Why?
|
| Infusions, Intravenous | 2 | 2012 | 2217 | 0.080 |
Why?
|
| Nursing Homes | 1 | 2017 | 1083 | 0.080 |
Why?
|
| Injections, Subcutaneous | 1 | 2011 | 672 | 0.080 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 2 | 1986 | 100 | 0.080 |
Why?
|
| Photic Stimulation | 2 | 2013 | 1984 | 0.080 |
Why?
|
| Education, Nursing, Continuing | 1 | 2009 | 69 | 0.080 |
Why?
|
| Electrical Equipment and Supplies | 1 | 2009 | 28 | 0.080 |
Why?
|
| Cost of Illness | 2 | 2024 | 1937 | 0.080 |
Why?
|
| Adolescent | 8 | 2023 | 88271 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 2254 | 0.080 |
Why?
|
| Kidney Transplantation | 1 | 2003 | 4240 | 0.080 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2016 | 940 | 0.080 |
Why?
|
| Health Maintenance Organizations | 2 | 2002 | 658 | 0.080 |
Why?
|
| Qualitative Research | 3 | 2014 | 3016 | 0.080 |
Why?
|
| Medicaid | 2 | 2014 | 2814 | 0.080 |
Why?
|
| Glasgow Coma Scale | 2 | 2007 | 579 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2001 | 3048 | 0.080 |
Why?
|
| Diabetes, Gestational | 1 | 2018 | 1250 | 0.080 |
Why?
|
| Mentors | 1 | 2014 | 663 | 0.080 |
Why?
|
| Postoperative Complications | 2 | 2016 | 15634 | 0.080 |
Why?
|
| Self Efficacy | 2 | 2009 | 636 | 0.070 |
Why?
|
| Islets of Langerhans | 2 | 2024 | 1341 | 0.070 |
Why?
|
| Physicians, Primary Care | 1 | 2014 | 618 | 0.070 |
Why?
|
| Preoperative Care | 2 | 2009 | 2242 | 0.070 |
Why?
|
| Lactates | 2 | 1986 | 401 | 0.070 |
Why?
|
| Quality of Life | 4 | 2019 | 13362 | 0.070 |
Why?
|
| Overweight | 1 | 2018 | 2418 | 0.070 |
Why?
|
| Sciatic Nerve | 1 | 1990 | 618 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 10755 | 0.070 |
Why?
|
| Inservice Training | 1 | 2009 | 375 | 0.070 |
Why?
|
| Urban Population | 1 | 2015 | 2035 | 0.070 |
Why?
|
| Injury Severity Score | 2 | 2007 | 1045 | 0.070 |
Why?
|
| New York City | 1 | 2009 | 730 | 0.070 |
Why?
|
| Postprandial Period | 2 | 2006 | 314 | 0.070 |
Why?
|
| Sebum | 1 | 2006 | 17 | 0.070 |
Why?
|
| Sebaceous Glands | 1 | 2006 | 42 | 0.070 |
Why?
|
| Oxaloacetates | 1 | 1985 | 5 | 0.070 |
Why?
|
| Quinolinic Acids | 1 | 1985 | 15 | 0.070 |
Why?
|
| Theophylline | 1 | 1986 | 131 | 0.070 |
Why?
|
| Nursing Staff, Hospital | 1 | 2009 | 348 | 0.060 |
Why?
|
| Pressure Ulcer | 1 | 2007 | 157 | 0.060 |
Why?
|
| Fenofibrate | 1 | 2006 | 87 | 0.060 |
Why?
|
| Drug Therapy, Combination | 3 | 2007 | 6305 | 0.060 |
Why?
|
| Decision Making | 2 | 2018 | 3925 | 0.060 |
Why?
|
| Protein Kinase C | 1 | 1990 | 1202 | 0.060 |
Why?
|
| Pyruvates | 1 | 1985 | 83 | 0.060 |
Why?
|
| Drug Utilization | 1 | 2012 | 1188 | 0.060 |
Why?
|
| Health Services Research | 1 | 2013 | 1807 | 0.060 |
Why?
|
| Faculty, Medical | 1 | 2014 | 1205 | 0.060 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 1985 | 48 | 0.060 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 1986 | 213 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2017 | 10083 | 0.060 |
Why?
|
| PPAR alpha | 1 | 2006 | 175 | 0.060 |
Why?
|
| Hyperlipidemias | 2 | 2007 | 771 | 0.060 |
Why?
|
| Enteral Nutrition | 1 | 2011 | 794 | 0.060 |
Why?
|
| Brachial Artery | 1 | 2006 | 366 | 0.060 |
Why?
|
| Gluconeogenesis | 1 | 1985 | 185 | 0.060 |
Why?
|
| Retrospective Studies | 7 | 2021 | 80673 | 0.060 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 825 | 0.060 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2005 | 353 | 0.060 |
Why?
|
| Database Management Systems | 1 | 2005 | 256 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 2372 | 0.060 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1990 | 1116 | 0.060 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2009 | 928 | 0.060 |
Why?
|
| Reference Values | 2 | 2008 | 4922 | 0.060 |
Why?
|
| Information Dissemination | 1 | 2012 | 1126 | 0.060 |
Why?
|
| Hemostasis | 1 | 2006 | 470 | 0.060 |
Why?
|
| Glycemic Index | 1 | 2006 | 396 | 0.060 |
Why?
|
| Lipolysis | 1 | 1985 | 210 | 0.060 |
Why?
|
| Glucose | 3 | 2006 | 4341 | 0.050 |
Why?
|
| Counseling | 1 | 2011 | 1536 | 0.050 |
Why?
|
| Medical Records | 1 | 2009 | 1409 | 0.050 |
Why?
|
| Morbidity | 1 | 2009 | 1750 | 0.050 |
Why?
|
| Glucose Tolerance Test | 1 | 2006 | 1178 | 0.050 |
Why?
|
| PPAR gamma | 1 | 2006 | 483 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2008 | 4014 | 0.050 |
Why?
|
| Cataract | 1 | 2009 | 832 | 0.050 |
Why?
|
| Child Day Care Centers | 1 | 2023 | 122 | 0.050 |
Why?
|
| Clinical Competence | 2 | 2016 | 4786 | 0.050 |
Why?
|
| International Cooperation | 1 | 2009 | 1423 | 0.050 |
Why?
|
| Documentation | 1 | 2009 | 898 | 0.050 |
Why?
|
| Pilot Projects | 3 | 2015 | 8639 | 0.050 |
Why?
|
| Rats, Inbred Strains | 3 | 1990 | 2087 | 0.050 |
Why?
|
| Social Support | 1 | 2012 | 2175 | 0.050 |
Why?
|
| Hypolipidemic Agents | 1 | 2006 | 609 | 0.050 |
Why?
|
| 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone | 3 | 1986 | 7 | 0.050 |
Why?
|
| Aging | 1 | 2020 | 8701 | 0.050 |
Why?
|
| Epinephrine | 1 | 1985 | 792 | 0.050 |
Why?
|
| Dietary Carbohydrates | 1 | 2006 | 891 | 0.050 |
Why?
|
| Rats | 8 | 2000 | 23713 | 0.050 |
Why?
|
| Urinary Tract Infections | 1 | 2007 | 802 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 15308 | 0.040 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 2000 | 19 | 0.040 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2006 | 1488 | 0.040 |
Why?
|
| Liver | 4 | 1996 | 7513 | 0.040 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 58946 | 0.040 |
Why?
|
| Regional Blood Flow | 2 | 2013 | 1498 | 0.040 |
Why?
|
| Glaucoma | 1 | 2009 | 1186 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2005 | 2081 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 4849 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 10213 | 0.040 |
Why?
|
| Surgical Procedures, Operative | 1 | 2009 | 1923 | 0.040 |
Why?
|
| Incidence | 1 | 2016 | 21357 | 0.040 |
Why?
|
| Health Status | 2 | 2009 | 4077 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 3689 | 0.040 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2004 | 1724 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 1996 | 3577 | 0.040 |
Why?
|
| Diabetic Nephropathies | 1 | 2004 | 972 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2003 | 2643 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2004 | 1469 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2007 | 2247 | 0.040 |
Why?
|
| Mid-Atlantic Region | 1 | 2016 | 24 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2008 | 5249 | 0.040 |
Why?
|
| Culture Media | 1 | 2019 | 894 | 0.040 |
Why?
|
| Preconception Care | 1 | 2018 | 141 | 0.030 |
Why?
|
| Transferases | 1 | 1996 | 71 | 0.030 |
Why?
|
| Farnesyltranstransferase | 1 | 1996 | 71 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2007 | 2630 | 0.030 |
Why?
|
| Arteriosclerosis | 1 | 2000 | 1056 | 0.030 |
Why?
|
| Chromones | 1 | 1996 | 148 | 0.030 |
Why?
|
| Europe | 1 | 2022 | 3422 | 0.030 |
Why?
|
| Body Mass Index | 3 | 2009 | 12951 | 0.030 |
Why?
|
| 8-Bromo Cyclic Adenosine Monophosphate | 2 | 1986 | 73 | 0.030 |
Why?
|
| Pneumonia | 1 | 2007 | 2142 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 2007 | 1923 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2015 | 22157 | 0.030 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1996 | 489 | 0.030 |
Why?
|
| Arterioles | 1 | 2015 | 250 | 0.030 |
Why?
|
| Child | 5 | 2023 | 80134 | 0.030 |
Why?
|
| Pyridines | 1 | 1985 | 2872 | 0.030 |
Why?
|
| Kinetics | 3 | 1987 | 6312 | 0.030 |
Why?
|
| Sepsis | 1 | 2007 | 2586 | 0.030 |
Why?
|
| Survival Rate | 1 | 2007 | 12727 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 1985 | 3309 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2018 | 904 | 0.030 |
Why?
|
| Morpholines | 1 | 1996 | 581 | 0.030 |
Why?
|
| Health Services Needs and Demand | 2 | 2012 | 1401 | 0.030 |
Why?
|
| Pluripotent Stem Cells | 1 | 2019 | 792 | 0.030 |
Why?
|
| Cardiomyopathies | 1 | 2004 | 2021 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2000 | 1780 | 0.020 |
Why?
|
| Goals | 1 | 2017 | 708 | 0.020 |
Why?
|
| Mitral Valve | 1 | 2000 | 1465 | 0.020 |
Why?
|
| Time Factors | 3 | 2019 | 39953 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 39121 | 0.020 |
Why?
|
| Calcinosis | 1 | 2000 | 1477 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1996 | 1168 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2001 | 6507 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2024 | 2363 | 0.020 |
Why?
|
| Heart Rate | 2 | 2013 | 4196 | 0.020 |
Why?
|
| Trifluoperazine | 1 | 1990 | 37 | 0.020 |
Why?
|
| Polymyxin B | 1 | 1990 | 44 | 0.020 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 1990 | 56 | 0.020 |
Why?
|
| Asthma | 1 | 2010 | 6229 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2019 | 1600 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 1987 | 5662 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 1409 | 0.020 |
Why?
|
| Lactic Acid | 2 | 1986 | 1139 | 0.020 |
Why?
|
| Graft Rejection | 1 | 2003 | 4479 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2017 | 1790 | 0.020 |
Why?
|
| Diglycerides | 1 | 1990 | 176 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 20120 | 0.020 |
Why?
|
| Nursing Education Research | 1 | 2009 | 11 | 0.020 |
Why?
|
| Blood Flow Velocity | 2 | 2006 | 1374 | 0.020 |
Why?
|
| Chromatography, Gel | 1 | 1990 | 642 | 0.020 |
Why?
|
| Nursing Methodology Research | 1 | 2009 | 64 | 0.020 |
Why?
|
| Models, Nursing | 1 | 2009 | 46 | 0.020 |
Why?
|
| Phosphatidylserines | 1 | 1990 | 185 | 0.020 |
Why?
|
| Hospitals | 1 | 2023 | 3881 | 0.020 |
Why?
|
| Depression | 1 | 2009 | 8130 | 0.020 |
Why?
|
| Coronary Circulation | 1 | 2015 | 1611 | 0.020 |
Why?
|
| Isoquinolines | 1 | 1990 | 352 | 0.020 |
Why?
|
| Pregnancy | 2 | 2023 | 29872 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2015 | 1866 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2017 | 2487 | 0.020 |
Why?
|
| Transfection | 1 | 1996 | 5750 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 1996 | 1745 | 0.020 |
Why?
|
| Societies | 1 | 2008 | 107 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2022 | 54419 | 0.020 |
Why?
|
| Disease Progression | 1 | 2024 | 13506 | 0.020 |
Why?
|
| Writing | 1 | 2009 | 199 | 0.020 |
Why?
|
| Hospitalization | 1 | 2007 | 10712 | 0.020 |
Why?
|
| Total Quality Management | 1 | 2008 | 262 | 0.020 |
Why?
|
| Health Surveys | 2 | 2010 | 4036 | 0.020 |
Why?
|
| Phospholipids | 1 | 1990 | 784 | 0.020 |
Why?
|
| Phenylisopropyladenosine | 1 | 1986 | 14 | 0.020 |
Why?
|
| Gemfibrozil | 1 | 2006 | 30 | 0.020 |
Why?
|
| Models, Educational | 1 | 2009 | 373 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 1996 | 2864 | 0.020 |
Why?
|
| Concanavalin A | 1 | 1986 | 190 | 0.020 |
Why?
|
| Skin | 1 | 2000 | 4473 | 0.020 |
Why?
|
| Aminoquinolines | 1 | 1986 | 106 | 0.020 |
Why?
|
| Quinolinic Acid | 1 | 1985 | 67 | 0.020 |
Why?
|
| Asparagine | 1 | 1985 | 120 | 0.020 |
Why?
|
| Oleic Acids | 1 | 1985 | 72 | 0.020 |
Why?
|
| Oleic Acid | 1 | 1985 | 92 | 0.020 |
Why?
|
| Phenylephrine | 1 | 1986 | 293 | 0.020 |
Why?
|
| Animals | 8 | 2000 | 168083 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 1996 | 3700 | 0.020 |
Why?
|
| Risk | 1 | 2017 | 9614 | 0.020 |
Why?
|
| Insulin, Long-Acting | 1 | 2005 | 58 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2006 | 864 | 0.010 |
Why?
|
| Isotretinoin | 1 | 2006 | 134 | 0.010 |
Why?
|
| Vasopressins | 1 | 1986 | 351 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2015 | 4164 | 0.010 |
Why?
|
| Pyruvic Acid | 1 | 1985 | 203 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1987 | 1429 | 0.010 |
Why?
|
| Lipogenesis | 1 | 2006 | 214 | 0.010 |
Why?
|
| Insurance Claim Review | 1 | 2008 | 741 | 0.010 |
Why?
|
| Community Health Services | 1 | 2008 | 654 | 0.010 |
Why?
|
| Thiazolidinediones | 1 | 2006 | 460 | 0.010 |
Why?
|
| Cytosol | 1 | 1985 | 883 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2008 | 1436 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2006 | 1636 | 0.010 |
Why?
|
| Drug Monitoring | 1 | 2008 | 961 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1987 | 3060 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 3821 | 0.010 |
Why?
|
| Benchmarking | 1 | 2008 | 1045 | 0.010 |
Why?
|
| Lipids | 1 | 2012 | 3330 | 0.010 |
Why?
|
| Trauma Centers | 1 | 2006 | 936 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1996 | 12743 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2023 | 42217 | 0.010 |
Why?
|
| Sulfonamides | 1 | 1990 | 1977 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1996 | 18926 | 0.010 |
Why?
|
| Piperazines | 1 | 1990 | 2522 | 0.010 |
Why?
|
| Ligands | 1 | 2006 | 3266 | 0.010 |
Why?
|
| Diet | 1 | 2017 | 8047 | 0.010 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2000 | 352 | 0.010 |
Why?
|
| Point-of-Care Systems | 1 | 2008 | 1213 | 0.010 |
Why?
|
| Lipoproteins, HDL | 1 | 2002 | 675 | 0.010 |
Why?
|
| Metformin | 1 | 2005 | 906 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2000 | 1516 | 0.010 |
Why?
|
| Critical Illness | 1 | 2008 | 2709 | 0.010 |
Why?
|
| Protein Binding | 1 | 1987 | 9300 | 0.010 |
Why?
|
| Anxiety | 1 | 2009 | 4572 | 0.010 |
Why?
|
| Body Weight | 1 | 2005 | 4618 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 26068 | 0.010 |
Why?
|
| Prognosis | 2 | 2006 | 29672 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2009 | 14607 | 0.010 |
Why?
|
| Cholesterol | 1 | 2002 | 2902 | 0.010 |
Why?
|
| Signal Transduction | 1 | 1996 | 23415 | 0.010 |
Why?
|
| Heart Valve Diseases | 1 | 2000 | 1030 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 9455 | 0.010 |
Why?
|
| Logistic Models | 1 | 2006 | 13254 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2000 | 8164 | 0.000 |
Why?
|
| Socioeconomic Factors | 1 | 2002 | 7804 | 0.000 |
Why?
|
| Algorithms | 1 | 2008 | 14023 | 0.000 |
Why?
|
| Severity of Illness Index | 1 | 2000 | 15845 | 0.000 |
Why?
|